KAMADA LTD
KMDANasdaq
$7.05
↑ +2.0%Jul 17 close · end-of-day
Price
1Y↓ -3.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to AATD. It also provides Bramitob to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity.
- CEO
- Amir London
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 360
- Website
- kamada.com
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jul 13, 2026
May 13, 2026
- 67d agoKamada Ltd (KMDA) Q1 2026 Earnings Call Highlights: Strategic Growth Amid Shipment Delaysfinance.yahoo.com
- 68d agoKamada (KMDA) Q1 2026 Earnings Transcriptfool.com
- 68d agoKamada Ltd. Q1 2026 Earnings Call Summaryapp.moby.co
- 68d agoKamada Q1 Earnings Call Highlightsmarketbeat.com
- 68d agoKamada (KMDA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimatesfinance.yahoo.com
- 68d agoKamada Q1 2026 Earnings Call: Complete Transcriptfinance.yahoo.com
- 68d agoKamada (KMDA) Misses Q1 Earnings and Revenue Estimatesfinance.yahoo.com
- 68d agoEarnings Scheduled For May 13, 2026finance.yahoo.com
- 68d agoKamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Yearfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.